NCT03989531View on ClinicalTrials.gov

Adrecizumab in Cardiogenic Shock

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

April 4, 2019

Primary Completion Date

April 26, 2021

Study Completion Date

April 26, 2021

Conditions
Cardiogenic ShockEndothelial Dysfunction
Interventions
BIOLOGICAL

Adrecizumab

Drip infusion over 60 minutes

DRUG

Placebo

Drip infusion over 60 minutes

Trial Locations (3)

12203

University of Berlin, Campus Benjamin-Franklin, Berlin

20246

University Heart Center Hamburg, Hamburg

89081

University of Ulm, Ulm

All Listed Sponsors
lead

Dr. med. Mahir Karakas

OTHER

NCT03989531 - Adrecizumab in Cardiogenic Shock | Biotech Hunter | Biotech Hunter